Welcome to our dedicated page for ProKidney news (Ticker: PROK), a resource for investors and traders seeking the latest updates and insights on ProKidney stock.
ProKidney Corp. develops rilparencel, also described as REACT or Renal Autologous Cell Therapy, as an autologous cell therapy candidate for patients with advanced chronic kidney disease and diabetes. News about PROK centers on clinical data from REGEN-007, Phase 3 PROACT 1/REGEN-006 development, regulatory interactions with the FDA on the use of eGFR slope in an accelerated approval pathway, and scientific presentations in nephrology forums.
Company updates also cover quarterly and annual financial results, cash runway commentary, investor conference participation, and leadership additions tied to commercial planning for rilparencel.
ProKidney Corp. (Nasdaq: PROK) announces the addition of John M. Maraganore, Ph.D. and Jennifer Fox to its Board of Directors, enhancing its leadership team. Maraganore, with over 35 years of experience, previously founded Alnylam Pharmaceuticals and is an advisor at several investment funds. Fox brings over 25 years of healthcare investment banking experience, previously associated with Nuvation Bio and CitiGroup. Both appointees will support ProKidney’s mission to advance its REACT™ therapy for chronic kidney disease during a critical development phase.
ProKidney Corp. (Nasdaq: PROK) has appointed Dr. Kerry Cooper as Senior Vice President of Medical Affairs, enhancing its leadership in treating Chronic Kidney Disease (CKD). Dr. Cooper, previously with AstraZeneca, brings nearly 40 years of clinical and industry experience, having led nephrology programs and established strong ties within the kidney advocacy community. His expertise will be crucial as ProKidney advances its candidate REACT™, a novel therapy aimed at reversing CKD's progression. This appointment comes as ProKidney prepares for further clinical studies.
ProKidney Corp., focused on chronic kidney disease (CKD), commenced trading on Nasdaq as "PROK" on July 12, 2022, following a merger with Social Capital Suvretta Holdings Corp. III. The company raised approximately $597 million in gross proceeds, primarily to fund ongoing Phase 2 and 3 clinical trials for its lead therapy, REACT™. This innovative cell therapy aims to improve kidney function in late-stage CKD patients. The firm is guided by an experienced management team and has filed over 200 patents, underscoring its commitment to advancing CKD treatments.